- Investing Ideas
- Canadian Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Canadian Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
5
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
5 companies
Curaleaf Holdings
Market Cap: CA$3.6b
Engages in the retail and wholesale of cannabis products in the United States and internationally.
CURA
CA$13.17
7D
-9.5%
1Y
166.1%
Green Thumb Industries
Market Cap: CA$2.3b
Manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States.
GTII
CA$10.13
7D
-6.0%
1Y
15.2%
Cresco Labs
Market Cap: CA$508.6m
Cresco Labs Inc. cultivates, manufactures, and sells retail and medical cannabis products in the United States and Germany.
CL
CA$1.08
7D
-6.9%
1Y
9.1%
Grown Rogue International
Market Cap: CA$160.0m
Through its subsidiaries, engages in cultivation, manufacture, possession, sale, and distribution of marijuana in the United States.
GRIN
CA$0.66
7D
0%
1Y
20.0%
Medexus Pharmaceuticals
Market Cap: CA$158.3m
Operates as a pharmaceutical company in Canada and the United States.
MDP
CA$5.09
7D
-2.7%
1Y
66.3%